Drug Profile
IONIS AR 2.5Rx
Alternative Names: ARRx; AZD 5312; IONIS AR 2.5Rx; ISIS ARRX; ISIS AZ1Rx; ISIS-560131; ISIS-ARRxLatest Information Update: 12 Oct 2022
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer AstraZeneca; Ionis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer; Solid tumours
Most Recent Events
- 12 Oct 2022 Discontinued - Phase-II for Prostate cancer (Late-stage disease) in United Kingdom (IV)
- 12 Oct 2022 Discontinued - Phase-II for Prostate cancer (Late-stage disease) in USA (IV)
- 17 Sep 2021 Flamingo Therapeutics enters into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies including IONIS AR 2.5Rx to treat various forms of cancer